Pfizer Murtiashaw Lecture in ChemsitryFriday, April 21, 2017 - 4:00pm
Location: Jones Physical Science Center, Room 006
Speaker: Dr. Angela Puchlopek-Demenci
Topic: Commercial Rout Development of a SMO Inhibitor
Abstract: PF-04449913, a smoothened receptor (SMO) inhibitor, is currently being studied for the treatment of hematological-based cancers. To support on-going drug development, a practical, scalable synthesis was desired to address the key synthetic challenge: effective installation of the anti- stereogenic centers at the 2,4-positions of the core piperidine. Development of a commercial process for PF- 04449913 has resulted in a concise, asymmetric synthesis which features an enzymatic transamination with concurrent dynamic kinetic resolution (DKR) of an intermediate 4-piperidone to establish the two stereogenic centers required in only a single step. This highly efficient reaction renders the desired anti-amino piperidine in >10:1 d.r. and >99% ee. In total, PF-04449913 is rapidly constructed in only five steps with 40% overall yield. The development of a commercial process for PF-04449913 is described herein.
Sponsored by the College of Arts and Sciences and the Department of Chemistry and Biochemistry
Pfizer Murtiashaw Lecture in Chemistry, April 21, 2017